|
|
|
|
|
|
|
09.11.26 - 13:06
|
Ionis reports third quarter 2026 financial results and highlights progress on key programs (Business Wire)
|
|
|
– ZANVASTRO™ (zilganersen) first approved medicine for Alexander disease; first independent launch underway from leading neurology pipeline –
– TRYNGOLZA® (olezarsen) 2026 product sales guidance lowered as sHTG launch ramps more gradually than expected reflecting early dynamics of establishing a new treatment paradigm –
– DAWNZERA® (donidalorsen) launch momentum continues; reaffirming 2026 product revenue guidance –
– Reaffirming 2026 total revenue, operating loss and cash guidance –CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the “Company”) today reported financial results and provided key updates for the third quarter ended September 30, 2026.
“In 2026, we continue to advance innovative medicines for people with serious diseases, underscored by three approvals for groundbreaking first-in-class medicines, two of which are Ionis-owned,” said Brett P. Monia, Ph.D., chief executive officer of Ionis. “TRYNGOLZA, our first launch in a large indic...
|
|
|
|
|
|
|
|
|
02.11.26 - 22:33
|
Ionis to hold third quarter 2026 financial results webcast (Business Wire)
|
|
|
Webcast scheduled for Monday, November 9 at 9:00 a.m. Eastern TimeCARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Monday, November 9 at 9:00 a.m. Eastern Time to discuss its third quarter 2026 financial results and highlight progress on key programs.
The webcast may be accessed at https://ir.ionis.com/events-and-presentations/upcoming-events. A replay will be available for a limited time at the same address.
About Ionis Pharmaceuticals, Inc.
For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has marketed medicines and a leading pipeline in neurology, cardiometabolic disease and select areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coup...
|
|
|
|
|
|
|
|
|
|
|
15.10.26 - 19:15
|
Ionis Pharmaceuticals Aktie: Milliardenpotenzial für neues Medikament! (Aktiencheck)
|
|
|
Zürich (www.aktiencheck.de) - Ionis Pharmaceuticals-Aktienanalyse der UBS:
UBS habe die Aktie von Ionis Pharmaceuticals Inc. (ISIN: US4622221004, WKN: A2ACMZ, Ticker-Symbol: ISI, NASDAQ-Symbol: IONS) von "neutral" auf "buy" hochgestuft und das Kursziel von 46 auf 88 USD erhöht. Das entspreche einer spektakulären Kurszielanhebung um rund 91,3%. [mehr]...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
